USPTO Patent Application for Tau Phospho Binding Antibodies

ChangeBridge: Patent Apps - Peptides (C07K)

Published September 15th, 2025

Detected March 23rd, 2026

Summary

The USPTO has published a patent application (US20260079168A1) for Tau phospho binding antibodies and antigen binding fragments thereof. The application, filed on September 15, 2025, relates to methods for detecting Tau phospho (Thr217) and potential diagnostic or therapeutic uses for diseases associated with it.

View original document View source feed page

What changed

This document is a publication of a United States Patent and Trademark Office (USPTO) patent application, specifically US20260079168A1, filed on September 15, 2025. The application details "TAU PHOSPHO (THR217) BINDING ANTIBODIES AND ANTIGEN BINDING FRAGMENTS THEREOF," including their use in detecting Tau phospho (Thr217) and potential applications in diagnosing or treating diseases associated with this biomarker.

As this is a patent application publication, it does not impose immediate regulatory obligations or compliance deadlines on regulated entities. However, it signals potential future developments in diagnostic and therapeutic technologies related to Tau phospho (Thr217), which may be relevant for pharmaceutical companies, medical device makers, and healthcare providers involved in Alzheimer's disease research or diagnostics.

Source document (simplified)

← USPTO Patent Applications

TAU PHOSPHO (THR217) BINDING ANTIBODIES AND ANTIGEN BINDING FRAGMENTS THEREOF

Application US20260079168A1 Kind: A1 Mar 19, 2026

Inventors

Efthalia CHRONOPOULOU, Patricia Hiroko TANI, Giovanni SUAREZ, Joseph Corey EVANS

Abstract

The technology relates in part to antibodies or antigen-binding fragments thereof that bind Tau phosphorylated at threonine 217 (Tau phospho (Thr217)) or a portion thereof, as well as methods, systems and kits for detection of Tau phospho (Thr217). In certain aspects, the technology relates to antibodies or antigen binding fragments thereof for use in determining levels of Tau phospho (Thr217) in a sample containing or suspected of containing Tau phospho (Thr217). In some aspects, the technology relates to antibodies or antigen-binding fragments thereof for use in diagnosing or treating an individual with or suspected of having a disease or disorder associated with Tau phospho (Thr217).